SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-031639
Filing Date
2024-08-13
Accepted
2024-08-13 16:30:54
Documents
84
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1035431
2 ex10-1.htm EX-10.1 84992
3 ex31-1.htm EX-31.1 11582
4 ex31-2.htm EX-31.2 11255
5 ex32-1.htm EX-32.1 6518
6 ex32-2.htm EX-32.2 6582
7 form10-q_001.jpg GRAPHIC 7032
  Complete submission text file 0001493152-24-031639.txt   6201198

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE erna-20240630.xsd EX-101.SCH 58648
9 XBRL CALCULATION FILE erna-20240630_cal.xml EX-101.CAL 70230
10 XBRL DEFINITION FILE erna-20240630_def.xml EX-101.DEF 233626
11 XBRL LABEL FILE erna-20240630_lab.xml EX-101.LAB 462489
12 XBRL PRESENTATION FILE erna-20240630_pre.xml EX-101.PRE 375695
87 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 767291
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-11460 | Film No.: 241202183
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)